These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 10928333)

  • 1. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI.
    Eschbach JW
    Semin Nephrol; 2000 Jul; 20(4):320-9. PubMed ID: 10928333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons from NKF-DOQI: iron management.
    Van Wyck DB
    Semin Nephrol; 2000 Jul; 20(4):330-4. PubMed ID: 10928334
    [No Abstract]   [Full Text] [Related]  

  • 3. Caring for the renal failure patient: optimizing iron therapy.
    Folkert VW; Javier AM; O'Mara NB
    Nephrol Nurs J; 2002 Dec; 29(6):586-93; quiz 594-5. PubMed ID: 12596608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
    Gejyo F; Saito A; Akizawa T; Akiba T; Sakai T; Suzuki M; Nishi S; Tsubakihara Y; Hirakata H; Bessho M;
    Ther Apher Dial; 2004 Dec; 8(6):443-59. PubMed ID: 15663544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
    Berns JS
    Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management.
    Kanbay M; Perazella MA; Kasapoglu B; Koroglu M; Covic A
    Blood Purif; 2010; 29(1):1-12. PubMed ID: 19816014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Is the management of anemia in hemodialysis patients improving in France? Results of the DiaNE study].
    Kessler M; Landais P; Canivet E; Yver L; Bataille P; Brillet G; Commenges B; Koné S
    Nephrol Ther; 2009 Apr; 5(2):114-21. PubMed ID: 19042175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of poor responders to erythropoietin among children undergoing hemodialysis.
    Seeherunvong W; Rubio L; Abitbol CL; Montané B; Strauss J; Diaz R; Zilleruelo G
    J Pediatr; 2001 May; 138(5):710-4. PubMed ID: 11343048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in erythropoietin therapy in the U.S. dialysis population: 1995 to 1998.
    Kimmel PL; Greer JW; Milam RA; Thamer M
    Semin Nephrol; 2000 Jul; 20(4):335-44. PubMed ID: 10928335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjusting i.v. iron and EPO doses in patients on hemodialysis prior to continuing surgery: can we protect our patients education from iron-deficiency anemia?
    Deaver K; Bennington L
    Nephrol Nurs J; 2006; 33(4):430-7; quiz 438. PubMed ID: 17002001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
    J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis.
    Berns JS; Mosenkis A
    Hemodial Int; 2005 Jan; 9(1):7-22. PubMed ID: 16191049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
    Dukkipati R; Kalantar-Zadeh K
    Nephrol News Issues; 2007 Jan; 21(1):34-8. PubMed ID: 17269263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment.
    Fishbane S; Kalantar-Zadeh K; Nissenson AR
    Semin Dial; 2004; 17(5):336-41. PubMed ID: 15461737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timely correction of anemia at the initiation of dialysis. Case study of the anemic patient.
    Breiterman-White R
    Nephrol Nurs J; 2002 Oct; 29(5):469-72. PubMed ID: 12434453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
    Sikole A; Spasovski G; Zafirov D; Polenakovic M
    Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia of chronic renal failure: new treatment alternative.
    Seiler S
    CANNT J; 2000; 10(3):35-9, 43-8; quiz 40-2, 49-51. PubMed ID: 11799582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.